CIK 0001517022
- Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 208756903
- Phone
- +1 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- 4 Shares withheld for taxes SVP, CFO & Treasurer gave up 22,235 shares (to pay taxes)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Exercise or conversion CEO and President acquired 100,000 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award SVP, Chief Medical Officer acquired 29,400 shares (grant or award)
- 4 Grant or award SVP, Chief Business Officer acquired 19,400 shares (grant or award)
- 4 Grant or award SVP, General Counsel, Sec. acquired 17,500 shares (grant or award)
- 4 Grant or award CEO and President acquired 88,900 shares (grant or award)
- 4 Grant or award SVP, CFO & Treasurer acquired 19,500 shares (grant or award)
- 4 Grant or award SVP, Chief Development Officer acquired 17,500 shares (grant or award)
- 4 Open-market sale Director sold 1,000 shares at $14.62 ($14,620)
- 4 Open-market sale Director sold 1,188 shares at $19.64 ($23,332)
- 4 Open-market sale SVP, General Counsel, Sec. sold 7,803 shares at an average $19.89 ($155,188)
Page 12 of 19 · 378 filings